577 related articles for article (PubMed ID: 16384813)
1. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.
de Leon J; Armstrong SC; Cozza KL
Psychosomatics; 2006; 47(1):75-85. PubMed ID: 16384813
[TBL] [Abstract][Full Text] [Related]
2. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
3. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.
de Leon J
Expert Rev Mol Diagn; 2006 May; 6(3):277-86. PubMed ID: 16706732
[TBL] [Abstract][Full Text] [Related]
4. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping.
de Leon J; Susce MT; Johnson M; Hardin M; Maw L; Shao A; Allen AC; Chiafari FA; Hillman G; Nikoloff DM
CNS Spectr; 2009 Jan; 14(1):19-34. PubMed ID: 19169185
[TBL] [Abstract][Full Text] [Related]
5. Clinical applications of CYP genotyping in psychiatry.
Spina E; de Leon J
J Neural Transm (Vienna); 2015 Jan; 122(1):5-28. PubMed ID: 25200585
[TBL] [Abstract][Full Text] [Related]
6. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
7. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?
Herbild L; Andersen SE; Werge T; Rasmussen HB; Jürgens G
Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):266-72. PubMed ID: 23731498
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
[TBL] [Abstract][Full Text] [Related]
9. Applications of CYP450 testing in the clinical setting.
Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
Naujokaitis D; Asmoniene V; Kadusevicius E
Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
Desta Z; Zhao X; Shin JG; Flockhart DA
Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
[TBL] [Abstract][Full Text] [Related]
12. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
[TBL] [Abstract][Full Text] [Related]
13. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L
Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups.
Luo HR; Aloumanis V; Lin KM; Gurwitz D; Wan YJ
Am J Pharmacogenomics; 2004; 4(6):395-401. PubMed ID: 15651900
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics and psychopharmacotherapy.
Poolsup N; Li Wan Po A; Knight TL
J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
[TBL] [Abstract][Full Text] [Related]
16. Association between inherited CYP2D6/2C19 phenotypes and anticholinergic measures in elderly patients using anticholinergic drugs.
Kersten H; Wyller TB; Molden E
Ther Drug Monit; 2014 Feb; 36(1):125-30. PubMed ID: 24089073
[TBL] [Abstract][Full Text] [Related]
17. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing.
Wu AH
Arch Pathol Lab Med; 2013 Sep; 137(9):1232-6. PubMed ID: 23991737
[TBL] [Abstract][Full Text] [Related]
18. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
[TBL] [Abstract][Full Text] [Related]
19. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.
de Leon J
J Clin Psychopharmacol; 2007 Jun; 27(3):241-5. PubMed ID: 17502769
[No Abstract] [Full Text] [Related]
20. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
